Concomitant proton pump inhibitors with mycophenolate mofetil and the risk of rejection in kidney transplant recipients

Transplantation

Volumn 97, Issue 5, 2014, Pages 518-524

  Knorr, John P ^a   Sjeime, Mariel ^a   Braitman, Leonard E ^a   Jawa, Pankaj ^a   Zaki, Radi ^a   Ortiz, Jorge ^a  

^a EINSTEIN MEDICAL CENTER   (United States)

Author keywords

Drug drug interactions; Kidney transplant; Mycophenolate mofetil; Proton pump inhibitors; Rejection

Indexed keywords

CALCINEURIN INHIBITOR; ESOMEPRAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; STEROID; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; DRUG ANTAGONISM; DRUG EXPOSURE; DRUG SAFETY; DRUG USE; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; COHORT STUDIES; CONTINENTAL POPULATION GROUPS; DRUG INTERACTIONS; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; RISK FACTORS; TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84896319941     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000436100.65983.10     Document Type: Article

References (52)

1. Helderman JH, Bennett WM, Cibrik DM, et al. Immunosuppression: Practice and trends. Am J Transplant 2003; 3: 41
2. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60: 225
3. Knight SR, Russell NK, Barcena L, et al. Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: A systematic review. Transplantation 2009; 87: 785
4. Opelz G, Döhler B. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. Transplantation 2009; 87: 795
5. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9: S1
6. Cellcept (Mycophenolate Mofetil) [Package Insert]. San Francisco, CA: Genentech; 2012
7. Bunnapradist S, Ambühl PM. Impact of gastrointestinal-related side effects on mycophenolate mofetil dosing and potential therapeutic strategies. Clin Transplant 2008; 22: 815
8. Davies NM, Grinyó J, Heading R, et al. Gastrointestinal side effects of mycophenolic acid in renal transplant patients: A reappraisal. Nephrol Dial Transplant 2007; 22: 2440
9. Knoll GA, MacDonald I, Khan A, et al. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003; 14: 2381
10. Pelletier RP, Akin B, Henry ML, et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003; 17: 200
11. Tierce JC, Porterfield-Baxa J, Petrilla AA, et al. Impact ofmycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipients. Clin Transplant 2005; 19: 779
12. Laftavi MR, Hai F, Laftavi H, et al. Mycophenolic acid dose reductions result in poor long-Term renal allograft survival: Comparison between mycophenolate sodium and mycophenolate mofetil. Transplant Proc 2011; 43: 478
13. Bunnapradist S, Lentine KL, Burroughs TE, et al.Mycophenolatemofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 2006; 82: 102
14. Su VC, Greanya ED, Ensom MH. Impact of mycophenolate mofetil dose reduction on allograft outcomes in kidney transplant recipients on tacrolimus-based regimens: A systematic review. Ann Pharmacother February 8, 2011. Epub ahead of print
15. LangoneA,Doria C, Greenstein S, et al.Does reduction inmycophenolic acid dose compromise efficacy regardless of tacrolimus exposure level? An analysis of prospective data fromtheMycophenolic Renal Transplant (MORE) Registry. Clin Transplant 2012; 1
16. van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999; 68: 261
17. Kiberd BA, Lawen J, Fraser AD, et al. Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation. Am J Transplant 2004; 4: 1079
18. Lidgate D, BrandlM, HolperM, et al. Influence of ferrous sulfate on the solubility, partition coefficient, and stability of mycophenolic acid and the ester mycophenolate mofetil. Drug Dev Ind Pharm 2002; 28: 1275
19. Rupprecht K, Schmidt C, Raspé A, et al. Bioavailability ofmycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers. J Clin Pharmacol 2009; 49: 1196
20. Kiberd BA, Wrobel M, Dandavino R, et al. The role of proton pump inhibitors on early mycophenolic acid exposure in kidney transplantation: Evidence from the CLEAR study. Ther Drug Monit 2011; 33: 120
21. Miura M, Satoh S, Inoue K, et al. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. Ther Drug Monit 2008; 30: 46
22. Doesch AO, Mueller S, Konstandin M, et al. Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. Transplant Proc 2010; 42: 4243
23. Kofler S, Shvets N, Bigdeli AK, et al. Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipientsVa prospective case-controlled study. Am J Transplant 2009; 9: 1650
24. Kofler S, Deutsch MA, Bigdeli AK, et al. Proton pump inhibitor comedication reduces mycophenolate acid drug exposure in heart transplant recipients. J Heart Lung Transplant 2009; 28: 605
25. Kofler S, Wolf C, Shvets N, et al. The proton pump inhibitor pantoprazole and its interaction with enteric-coatedmycophenolate sodium in transplant recipients. J Heart Lung Transplant 2011; 30: 565
26. Gore JL, Pham PT, Danovitch GM, et al. Obesity and outcome following renal transplantation. Am J Transplant 2006; 6: 357
27. Kees MG, Steinke T, Moritz S, et al. Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteers. J Clin Pharmacol 2012; 52: 1265
28. Miner P Jr, Katz PO, Chen Y, et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: A five-way crossover study. Am J Gastroenterol 2003; 98: 2616
29. Schaier M, Scholl C, Scharpf D, et al. Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil. Rheumatology 2010; 49: 2061
30. Prichard PJ, Jones DB, Yeomans ND, et al. The effectiveness of ranitidine in reducing gastric acid-secretion decreases with continued therapy. Br J Clin Pharmacol 1986; 22: 663
31. Lachman L, Howden CW. Twenty-four-hour intragastric pH: Tolerance within 5 days of continuous ranitidine administration. Am J Gastroenterol 2000; 95: 57
32. Bullingham R, Shah J, Goldblum R, et al. Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients. Br J Clin Pharmacol 1996; 41: 513
33. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998; 34: 429
34. Kuypers DR, Ekberg H, Grinyó J, et al. Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients. Clin Pharmacokinet 2009; 48: 329
35. van Gelder T, Klupp J, Barten MJ, et al. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001; 23: 119
36. Langone A,Doria C,Greenstein S, et al.Does reduction inmycophenolic acid dose compromise efficacy regardless of tacrolimus exposure level? An analysis of prospective data fromtheMycophenolic Renal Transplant (MORE) Registry. Clin transplant 2013; 27: 15
37. Malat GE, Culkin C, Palya A, et al. African American kidney transplantation survival: The ability of immunosuppression to balance the inherent pre-And post-Transplant risk factors. Drugs 2009; 69: 2045
38. PescovitzMD, Guasch A, Gaston R, et al. Equivalent pharmacokinetics of mycophenolatemofetil in African-American and Caucasianmale and female stable renal allograft recipients. Am J Transplant 2003; 3: 1581
39. Neylan JF. Immunosuppressive therapy in high-risk transplant patients: Dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1997; 64: 1277
40. Tornatore KM, Sudchada P, Dole K, et al. Mycophenolic acid pharmacokinetics during maintenance immunosuppression in African American and Caucasian renal transplant recipients. J Clin Pharmacol 2011; 51: 1213
41. Neylan JF. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. Transplantation 1998; 65: 515
42. Barry A, Levine M. A systematic review of the effect of CYP3-5 genotype on the apparent oral clearance of tacrolimus in renal transplant recipients. Ther Drug Monit 2010; 32: 708
43. Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther 2000; 25: 333
44. Nardino RJ, Vender RJ, Herbert PN. Overuse of acid-suppressive therapy in hospitalized patients. Am J Gastroenterol 2000; 95: 3118
45. Batuwitage BT, Kingham JG, Morgan NE, et al. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J 2007; 83: 66
46. Cunningham R, Dale B, Undy B, et al. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003; 54: 243
47. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007; 102: 2047
48. Yang YX, Lewis JD, Epstein S, et al. Long-Term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947
49. Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of communityacquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004; 292: 1955
50. Hoorn EJ, van Der Hoek J, De Man RA, et al. A case series of proton pump inhibitor-induced hypomagnesemia. AmJ Kidney Dis 2010; 56: 112
51. Broeren MA, Geerdink EA, Vader HL, et al. Hypomagnesemia induced by several proton-pump inhibitors. Ann Intern Med 2009; 151: 755
52. Salvadori M, Holzer H, deMattos A, et al. Enteric-coatedmycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in De novo renal transplant patients. Am J Transplant 2004; 4: 231